655 related articles for article (PubMed ID: 27762511)
1. A Study of Effects of Pioglitazone and Rosiglitazone on Various Parameters in Patients of Type-2 Diabetes Mellitus with Special Reference to Lipid Profile.
Sharma SK; Verma SH
J Assoc Physicians India; 2016 Sep; 64(9):24-28. PubMed ID: 27762511
[TBL] [Abstract][Full Text] [Related]
2. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
3. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
[TBL] [Abstract][Full Text] [Related]
4. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes.
Berneis K; Rizzo M; Stettler C; Chappuis B; Braun M; Diem P; Christ ER
Expert Opin Pharmacother; 2008 Feb; 9(3):343-9. PubMed ID: 18220486
[TBL] [Abstract][Full Text] [Related]
6. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.
Chappuis B; Braun M; Stettler C; Allemann S; Diem P; Lumb PJ; Wierzbicki AS; James R; Christ ER
Diabetes Metab Res Rev; 2007 Jul; 23(5):392-9. PubMed ID: 17211855
[TBL] [Abstract][Full Text] [Related]
7. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
Olansky L; Marchetti A; Lau H
Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
[TBL] [Abstract][Full Text] [Related]
8. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone.
LaCivita KA; Villarreal G
Curr Med Res Opin; 2002; 18(6):363-70. PubMed ID: 12442884
[TBL] [Abstract][Full Text] [Related]
9. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
Khan MA; St Peter JV; Xue JL
Diabetes Care; 2002 Apr; 25(4):708-11. PubMed ID: 11919129
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital.
Hussein Z; Wentworth JM; Nankervis AJ; Proietto J; Colman PG
Med J Aust; 2004 Nov; 181(10):536-9. PubMed ID: 15540964
[TBL] [Abstract][Full Text] [Related]
11. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus.
Sahin M; Tutuncu NB; Ertugrul D; Tanaci N; Guvener ND
J Diabetes Complications; 2007; 21(2):118-23. PubMed ID: 17331860
[TBL] [Abstract][Full Text] [Related]
12. Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.
Chogtu B; Singh NP; Chawla S; Gupta U
Singapore Med J; 2009 Apr; 50(4):395-9. PubMed ID: 19421684
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
14. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
15. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
[TBL] [Abstract][Full Text] [Related]
16. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.
Boyle PJ; King AB; Olansky L; Marchetti A; Lau H; Magar R; Martin J
Clin Ther; 2002 Mar; 24(3):378-96. PubMed ID: 11952022
[TBL] [Abstract][Full Text] [Related]
17. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus.
Göke B;
Treat Endocrinol; 2002; 1(5):329-36. PubMed ID: 15832486
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.
Raskin P; Rappaport EB; Cole ST; Yan Y; Patwardhan R; Freed MI
Diabetologia; 2000 Mar; 43(3):278-84. PubMed ID: 10768088
[TBL] [Abstract][Full Text] [Related]
19. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
Tilden DP; Mariz S; O'Bryan-Tear G; Bottomley J; Diamantopoulos A
Pharmacoeconomics; 2007; 25(1):39-54. PubMed ID: 17192117
[TBL] [Abstract][Full Text] [Related]
20. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes.
Yilmaz H; Gursoy A; Sahin M; Guvener Demirag N
Acta Diabetol; 2007 Dec; 44(4):187-92. PubMed ID: 17726570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]